Results from thalassa-trial, the first pivotal placebo-controlled study examining the benefit of iron chelation with deferasirox (Exjade®, Novartis), an iron chelator, in patients with non-transfusion-dependent thalassemia (NTDT), show that deferasirox can significantly reduce iron overload. The researchers concluded that the drug is significantly better than placebo at… Continue
Added by Peter Hofland, PhD on December 13, 2011 at 9:00am —
Data reported today demonstrating that prolonged treatment with Brentuximab Vedotin (SGN-35; Adcetris™, Seattle Genetics) beyond 16 cycles of therapy was associated with clinically meaningful durations of response with a manageable safety profile. In addition, data were presented showing that Brentuximab Vedotin is a viable option for reducing tumor burden prior to allogeneic stem cell transplant. The data were presented at the… Continue
Added by Peter Hofland, PhD on December 12, 2011 at 2:30pm —
An experimental drug that works by blocking the export of key control molecules from the nucleus of cancer cells shows promise as a treatment for chronic lymphocytic leukemia (CLL) and other incurable B-cell malignancies, according to a new study by researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove… Continue
Added by Peter Hofland, PhD on December 12, 2011 at 8:30am —
An estimated 90,000 to 100,000 Americans are affected each year by sickle cell disease (SCD), a serious disorder that causes normal red blood cells to become rigid and form in a crescent “sickle” shape. The abnormal shape of these cells causes them to clump together and become embedded in the blood vessels of organs, causing pain, infection, potential organ damage, and stroke. Even with advancements in drug therapies and prevention methods, safe and effective treatment options… Continue
Added by Peter Hofland, PhD on December 11, 2011 at 11:30am —
Results from a multi-center Phase I study that explored multiple dosing schedules of oral azacitidine in 23 patients with acute myeloid leukemia (AML), myelodysplastic syndromes or chronic myelomonocytic leukemia (CMML) who were not candidates for other therapies or who had failed previous regimens showed a potential treatment benefit. Findings from this study were presented during the 53rd Annual Meeting of the American Society… Continue
Added by Peter Hofland, PhD on December 10, 2011 at 9:00pm —
Researcher of St. Jude Children's Research Hospital have identified a key immune system regulator, a protein that serves as a gatekeeper in the white blood cells that produce the "troops" to battle specific infections. The findin will provide insight into immune system biology and identify the mechanism that keeps white blood cell activity at a minimum until the specific immune response is needed.… Continue
Added by Peter Hofland, PhD on July 18, 2011 at 7:30am —
Epoetin alfa (Epogen®, Procrit®)was initially approved by the U.S. Food and Drug Administration (FDA) in 1989 to treat some forms of anemia resulting from chronic kidney disease (CKD). It also is used to treat anemia in patients with HIV infection who are receiving zidovudine (Retrovir®)and in… Continue
Added by Peter Hofland, PhD on June 24, 2011 at 7:00pm —
Results from a new study presented at the 16th Congress of the European Hematology Association in London (United Kingdom) shows possible advantages of stem cell transplantation for patients with Multiple Myeloma, a cancer of plasma cells. Dr Antonio Palumbo: “This study shows a longer progression-free survival time with hematopoietic stem cell transplantation in comparison to conventional chemotherapy.”… Continue
Added by Peter Hofland, PhD on June 10, 2011 at 4:30pm —
Interim results from an international, single-arm study ("209 study") evaluating the safety and efficacy of romiplostim (Nplate®, Amgen) in adults with primary immune thrombocytopenia (ITP) - a rare blood disorder - demonstrated that the investigational drug induced a rapid platelet response with a good safety profile in adult ITP patients with low platelet counts and bleeding… Continue
Added by Peter Hofland, PhD on June 10, 2011 at 10:00am —
Scientists identify in the journal Nature a new molecular pathway used to suppress blood vessel branching in the developing retina – a finding with potential therapeutic value for fighting diseases of the retina and a variety of cancers.
The researchers report that myeloid cells, blood cells involved in the immune system, use this molecular pathway to guide… Continue
Added by Peter Hofland, PhD on May 29, 2011 at 10:00am —
Leukemia is the most common childhood cancer whick also occurs in adults. Now researchers working with zebrafish at Huntsman Cancer Institute (HCI) at the University of Utah have identified previously undiscovered high-risk genetic features in T-cell acute lymphocytic leukemia (T-ALL), according to an article published online today in the cancer research journal… Continue
Added by Peter Hofland, PhD on May 10, 2011 at 5:00pm —
San Diego and Seattle-based biopharmaceutical company HemaQuest Pharmaceuticals, Inc. which focuses its clinical research on developing small molecule therapeutics based on its proprietary Short Chain Fatty Acid Derivatives or SCFADs technologies to treat hemoglobin diseases, earlier today announced that clinical investigators have enrolled the first patient in a randomized multi-dose Phase II study of HQK-1001 in patients with… Continue
Added by Peter Hofland, PhD on April 25, 2011 at 2:00pm —
Follicular lymphoma (FL) is the most common type of non-Hodgkin Lymphoma (NHL). In 2010 an estimated 65,540 people in the US were diagnosed with NHL, and follicular lymphoma accounts for between 15 to 20%t of these case. Overall, about 35% of all NHLs in the USA, and 22% worldwide, are diagnosed as FL.  Continue
Follicular lymphoma, also called 'indolent' or 'low-grade' lymphoma, is a slow-growing neoplasm arising from follicle center-derived B cells, both…
Added by Peter Hofland, PhD on December 5, 2010 at 9:00am —
The future of colon cancer screening may be surprisingly simple. ColoMarker™ (EDP Biotech, Knoxville, TN) an innovative blood test to detect the early stages of colon cancer is generating plenty of attention from a wide audience, including from some of the world’s leading researchers in cancer biomarkers and gastrointestinal medicine.
ColoMarker, is developed by EDP Biotech, a US-based medical research… Continue
Added by Peter Hofland, PhD on November 17, 2010 at 5:00pm —
Twenty percent fewer lung cancer deaths seen among those screened with CT than with chest X-ray in a trial conducted by the American College of Radiology Imaging Network and the Lung Screening Study group.
The National Cancer Institute (NCI) released initial results from a large-scale clinical trial evaluating whether lung cancer screening with low-dose helical computed tomography (CT) or standard chest X-rays saves lives.
Lung cancer, most… Continue
Added by Peter Hofland, PhD on November 4, 2010 at 9:00am —
Sermo, the largest online community where over 115,000 practicing physicians discuss a wide range of issues from clinical cases to advice about drugs and practice management, today published a free Sermo Report titled, 'Physician Participation in the ESA REMS Program.' The report covers physician perceptions and participation rates in the FDA-required… Continue
Added by Peter Hofland, PhD on October 21, 2010 at 11:00am —
At the recent World Federation of Haemophilia's (WFH's) world congress in Buenos Aires, Argentina, Octapharma AG sponsored a symposium entitled “Modern Treatment Options for von Willebrand Disease (VWD) and Haemophilia B – What are the Benefits for the Patients?”, which took place on July 12, 2010.… Continue
Added by Peter Hofland, PhD on September 16, 2010 at 2:00am —
For cancer patients, who have an increased risk of developing venous thromboembolism (VTE) due to a hyperactive blood coagulation system, there is now an enhanced risk model to predict their chance of developing blood clots, according to a recent study published today in Blood, the journal of the American Society of Hematology.
VTE, the formation of blood clots in the veins, develops in up to 20% of cancer patients and is one of the leading causes of death… Continue
Added by Peter Hofland, PhD on September 9, 2010 at 10:30am —
Researchers at Whitehead Institute and Children's Hospital Boston have identified a protein, called Musashi 2, that is predictive of prognosis in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) patients.
High levels of Musashi 2 protein is associated with increased cell proliferation, decreased cell maturation, and multiple cancer-related cellular pathways in human leukemias. The protein and the cellular functions it affects could potentially… Continue
Added by Peter Hofland, PhD on July 8, 2010 at 9:30pm —
The Phase III international PRIMA trial results, presented at the 15th Congress of the European Hematology Association (EHA) taking place from June 10 to 13 at the Fira Barcelona Gran Via in Barcelona, Spain, show that two years of rituximab ‘maintenance’ therapy reduced the risk of follicular lymphoma recurrence by 50% in patients who responded to initial chemotherapy plus rituximab induction. Maintenance therapy is a longer-term treatment given after patients achieve remission,… Continue
Added by Peter Hofland, PhD on June 11, 2010 at 11:30pm —